3 Black bars depict annual budget impacts associated with suggested mass screening policy PLX4032 reforms which mandate the use of serum Cr

assay. Positive budget impacts on both panels imply that the reforms would result in the increase of medical care expenditure. a Policy 1 mandate serum Cr assay. b Policy 2 mandate serum Cr assay and abandon dipstick test. Cr creatinine Discussion We estimate the budget impacts of CKD screening test in SHC, of which use has been found cost-effective elsewhere [12]. With regard to two reform policy options: mandate serum Cr assay in Trametinib manufacturer addition to the dipstick test (Policy 1), and mandate serum Cr assay and abandon dipstick test (Policy 2), both positive and increasing budget impacts are found in the fifteen-year time frame. Although there is no established rule for interpreting the results of budget impact analysis, estimated values of ¥963 million (US$9.63 million) to ¥4,129 million (US$41.29 million) per year over fifteen years are considerable amounts of money of limited resources. These amount to 0.0026 to 0.011 % of national medical care expenditure in 2010 [22], and 0.068 and 0.29 % of the annual increase between 2009 and 2010, ¥1,413,500 million (US$14,135 million), respectively.

Our case study exemplifies a situation where budgetary constraints, or affordability, matters to the use of cost-effective interventions which have been judged as worth using according to social willingness to pay for new intervention. The most impressive

finding of this study, however, is the decreasing Selleck PSI-7977 additional expenditures of dipstick test only scenario, which become negative in just its second year. This suggests that the mandatory dipstick test under current practice would contain medical care expenditure, i.e. ‘decreasing annual national medical costs’. In other words, this is a valuable evidence that prevention saves life as well as money. And requiring dipstick test instead of serum Cr assay as a mandatory test item in SHC in 2008 may have been Montelukast Sodium a sensible choice. Due caution is needed to interpret the results of our budget impact analysis, since they depend on crucial assumptions. Positive budget impacts are found to be attributable to additional expenditure for curative care; however, for example, the analysis does not take medical advancement or health system development into account. In the coming 15 years, innovative therapeutic agents to prevent progression to ESRD are expected [23–26], and community-based CKD control intervention under collaboration between general practitioners and nephrologists is under study [27]. More prevention of ESRD should bring significant reduction in budget impact, since treatment of ESRD is most costly.